Cognoptix Inc
Cognoptix Inc, based in Marlborough, MA, is a pioneering company in the field of Alzheimer's diagnostics. Co-founded by Dr. Lee Goldstein and Dr. Leo Chylack of Brigham and Women's Hospital in Boston, Cognoptix has developed an innovative system that detects beta amyloid proteins, a hallmark of Alzheimer's disease, in the lens of the eye. Their non-invasive eye scanning technology provides a highly accurate, safe, simple, and cost-effective test for the early detection and diagnosis of Alzheimer's disease.
With a focus on interventional therapy for Alzheimer's, Cognoptix aims to provide an early warning system for the disease, empowering physicians and patients to take charge of their cognitive health. By detecting suspect beta amyloid proteins in the eye prior to the buildup of toxic plaques in the brain, Cognoptix's diagnostic platform offers a valuable tool for clinical, commercial, and academic research use. The company is actively seeking strategic alliances with pharmaceutical partners and academic institutes while preparing its diagnostic platform for clinical use.
Generated from the website
